Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1

被引:86
作者
Lu, Xinxing [1 ]
Chen, Dong [2 ]
Yang, Feiya [2 ]
Xing, Nianzeng [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Urol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Inst & Hosp, Chinese Acad Med Sci, Dept Urol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
prostate cancer; quercetin; lncRNA; MALAT1; PI3K/Akt; epithelial-to-mesenchymal transition; apoptosis; NONCODING RNA; ANDROGEN RECEPTOR; E-CADHERIN; METASTASIS; PROLIFERATION; EXPRESSION;
D O I
10.2147/CMAR.S241093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Prostate cancer (PC) is one of the most common carcinomas in men worldwide. The lack of effective therapies urges the development of novel therapeutic options against PC. Quercetin (Quer) is a flavonoid compound that has been shown to effectively inhibit PC in vitro and in vivo. However, the underlying mechanisms await elucidation. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. Previous data showed that quercetin promoted the apoptosis of fibroblast-like synoviocytes by upregulating MALAT1 in rheumatoid arthritis. However, we speculate that mechanisms are different in PC. Materials and Methods: Human PC cell line PC-3 and its xenograft tumor were chosen as in vitro and in vivo models for PC. A series of in vitro and in vivo functional experiments were carried out to elucidate the role of MALAT1 in quercetin treatment against PC. Western blot was performed to measure the expression of related proteins to explore underlying molecular mechanisms. Results: We showed for the first time that MALAT1 expression was significantly downregulated in quercetin-treated PC cells in a dose- and time-dependent manner. Also, quercetin inhibited the proliferation of PC cells and the growth of xenograft tumors. Moreover, quercetin suppressed EMT process, promoted apoptosis and deactivated PI3K/Akt signaling pathway during the progression of PC. MALAT1 overexpression in PC cells resulted in the resistance against quercetin treatment. Conclusion: Our study illustrated, for the first time, that MALAT1 played an important role in quercetin treatment against PC by inhibiting EMT process and promoting apoptosis, providing a new molecular basis for the application of quercetin in PC treatment.
引用
收藏
页码:1741 / 1750
页数:10
相关论文
共 35 条
[1]  
[Anonymous], 2019, ONCOGENE
[2]  
[Anonymous], 2010, Guide for the care and use of laboratory animals
[3]   Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics? [J].
Brito, Ana Filipa ;
Ribeiro, Marina ;
Abrantes, Ana Margarida ;
Pires, Ana Salome ;
Teixo, Ricardo Jorge ;
Tralhao, Jose Guilherme ;
Botelho, Maria Filomena .
CURRENT MEDICINAL CHEMISTRY, 2015, 22 (26) :3025-3039
[4]  
Chen HX, 2016, FRONT BIOSCI-LANDMRK, V21, P1084
[5]   Silencing of MALAT1 inhibits migration and invasion by sponging miR-1-3p in prostate cancer cells [J].
Dai, Xiaofan ;
Liang, Zuowen ;
Liu, Lingyun ;
Guo, Kaimin ;
Xu, Shengqi ;
Wang, Hongliang .
MOLECULAR MEDICINE REPORTS, 2019, 20 (04) :3499-3508
[6]   Silencing of lncRNA MALAT1 inhibits cell cycle progression via androgen receptor signaling in prostate cancer cells [J].
Dai, Xiaofan ;
Liu, Lingyun ;
Liang, Zuowen ;
Guo, Kaimin ;
Xu, Shengqi ;
Wang, Hongliang .
PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (04) :712-721
[7]   MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway [J].
Dong, Yongqiang ;
Liang, Guojun ;
Yuan, Bo ;
Yang, Chaoqun ;
Gao, Rui ;
Zhou, Xuhui .
TUMOR BIOLOGY, 2015, 36 (03) :1477-1486
[8]  
Fleshner N, 2005, CAN J UROL S1, V12, P94
[9]  
Fleshner Neil, 2005, Can J Urol, V12 Suppl 1, P14
[10]   A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer [J].
Gravdal, Karsten ;
Halvorsen, Ole J. ;
Haukaas, Svein A. ;
Akslen, Lars A. .
CLINICAL CANCER RESEARCH, 2007, 13 (23) :7003-7011